Developer docs
API playgroundTry for free, no card

Search company profiles

Axmed

Full company profile

uuid0000qqf

Namestring
Axmed
Legal namestring
Axmed
Websiteurl
axmedrx.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Axmed is a Basel, Switzerland-headquartered B2B digital marketplace that connects healthcare procurers in low- and middle-income countries (LMICs) with vetted global and regional pharmaceutical suppliers. Founded in 2024 with a regional hub in Nairobi, Kenya, the company targets governments, NGOs, and mission-driven private procurers in Sub-Saharan Africa and other emerging markets, addressing fragmented LMIC demand where traditional procurement markups of around 250% are commonplace. Its integrated platform combines a marketplace that aggregates demand and enables direct manufacturer contracting, a Logistics SaaS layer that coordinates with top global logistics partners, a Global Health Advisory service for procurement strategy, and embedded financing through the Revolving Inventory Financing Facility (RIFF) and a $5 million Gates Foundation-backed Matching Fund for maternal, newborn, and child health (MNCH) procurement. Axmed caps marketplace markup at 10% and reports redeploying 30% of profits back into the health systems it serves, while claiming average cost savings of around 35% for customers.

The business operates a transaction-fee model capped at 10%, supplemented by managed-services revenue from logistics coordination and financing arrangements, with go-to-market executed through enterprise field sales to governments and institutional buyers alongside partnership-driven introductions via NGOs and donor ecosystems. Named customers and partners include the Government of Burkina Faso ($7M REACH programme agreement for up to 16 million doses of azithromycin), LifeNet International, Every Pregnancy, MEDS Kenya, CHAN Nigeria, and Emcure Pharmaceuticals. By year-end 2025, Axmed reported reaching 4.2 million patients (up from ~750,000 in 2024), delivering over 1,800 metric tonnes of healthcare products across 5,000+ SKUs in 10+ therapeutic areas, with 130+ commercially active procurers and suppliers and 12x year-on-year revenue growth.

The company has raised approximately $13 million in total capital, comprising a $2 million seed round led by Founderful Ventures and roughly $11 million in non-dilutive grants from the Bill & Melinda Gates Foundation, and has publicly targeted operating in 20+ countries by end of 2026 and reaching 50 million patients within three years and 100 million within five years. Management includes co-founders Emmanuel Akpakwu (CEO), Felix Ohnmacht (CCO), Sofía Radley Searle (COO), and Mattia Albergante (CTO).

Short descriptiontext

Axmed is a Basel-headquartered B2B digital marketplace that aggregates demand from governments, NGOs, and healthcare procurers in low- and middle-income countries to procure essential medicines directly from vetted global pharmaceutical suppliers at lower cost.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
B2B healthcare marketplace, medical procurement platform, pharmaceutical supply chain, global health logistics, medicine financing solutions
Industry3 codes
PRIMARYBPAMAGAD
B2B Marketplaces & Wholesale Platforms
Business & Public Services/Web, Mobile & Digital Platforms/E-commerce Marketplaces & Shopping Platforms
SECONDARYHLAIAKAA
Pricing & Contracting Strategy
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYHLAIAKAI
Channel & Trade Strategy (Gross-to-Net, Distribution Economics)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
NAICS code3 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Wholesale Trade Agents and Brokers42512
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Healthcare Procurement Marketplace
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Marketplace Transaction Fees
TypeTransaction Fee
Description

Axmed operates a B2B marketplace that connects healthcare procurers with suppliers. The company caps its markup at 10% and redeploys 30% of its profits back into health systems it serves, indicating a transaction-based revenue model with a social-impact pricing structure.

axmed.com
2Logistics and Financing Services
TypeManaged Services
Description

Integrated financing solutions and logistics support are embedded in the platform, with the Revolving Inventory Financing Facility (RIFF) providing capital access to procurers. Revenue is derived from financing arrangements and logistics coordination services.

axmed.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Platform access and marketplace
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Axmed caps its marketplace markup at 10% and redeploys 30% of profits into health systems. Average cost savings for customers are 30-35% compared to market benchmarks. Specific pricing tiers are not publicly disclosed.

axmed.com
GTM typeB2B
B2B
Offering typeDigital Commerce or Conte…
Digital Commerce or Content
Core offering1 text field

Axmed operates a B2B digital marketplace that aggregates fragmented demand from healthcare procurers across low- and middle-income countries and connects them directly with vetted pharmaceutical manufacturers and suppliers. The platform integrates demand aggregation, price transparency, logistics coordination, and trade financing (RIFF and a $5M Matching Fund) to reduce medicine procurement costs by over 35% for governments, NGOs, and mission-driven private procurers in LMICs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 4.2 million patients reached in 2025, up from 750,000 in 2024
+5 more records
Product overview1 text field

Axmed operates a unified B2B technology platform for medicine procurement in low- and middle-income countries, comprising three core products: the Axmed Marketplace (B2B marketplace connecting procurers with suppliers), Logistics SaaS (end-to-end logistics support), and Global Health Advisory (GHA) services. The platform is complemented by two integrated financing solutions: the Revolving Inventory Financing Facility (RIFF) for affordable capital access and the $5M Axmed Matching Fund for MNCH procurement, all designed to work together to reduce costs by over 35% while expanding access to essential medicines across Africa and emerging markets.

Product and service4 records
1Axmed Marketplace
CategoryCore Product
Description

A global B2B marketplace connecting healthcare procurers in low- and middle-income countries with vetted pharmaceutical suppliers. The platform aggregates fragmented demand to negotiate directly with manufacturers, reducing procurement costs by over 35% and providing access to 5,000+ products across 10+ therapeutic areas.

2Logistics SaaS
CategoryCore Product
Description

Integrated end-to-end logistics solution connecting buyers with top global logistics partners to streamline delivery of medicines and healthcare products across LMICs.

3Global Health Advisory (GHA)
CategoryCore Product
Description

Advisory service supporting governments and institutional procurers with procurement strategy, health system strengthening, and access to capital for essential medicines procurement.

4Revolving Inventory Financing Facility (RIFF)
CategoryFinancing Solution
Description

An integrated supply capital facility and trade financing solution that bridges access to finance with access to quality medicines, empowering third-sector procurers to stock life-saving products in emerging markets.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Government of Burkina Faso (REACH Programme)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-19
Description

$7 million long-term supply agreement under the Resiliency through Azithromycin for Children (REACH) programme to deliver up to 16 million doses of quality-assured azithromycin to children under five in Burkina Faso over three years, supporting reduction of preventable child mortality from bacterial infections. The agreement operates through Burkina Faso's national health ecosystem.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Transformative partnership to expand access to essential maternal and newborn health products in Africa. LifeNet provides healthcare capacity building and training, while Axmed provides its procurement platform for medical supplies. The collaboration has already contributed to zero maternal deaths at a clinic in Northern Ghana and spans across underserved regions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to enhance access to affordable essential medicines for mothers and babies affected by conflict and crisis. Every Pregnancy partners gain access to affordable and quality medicines through Axmed's B2B marketplace, rooted in a shared mission to ensure safe pregnancies and healthy babies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Unite to combat maternal and newborn mortality and promote equitable healthcare access. The collaboration combines Emcure's pharmaceutical portfolio with Axmed's procurement platform to transform global health outcomes.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Axmed partners with MEDS Kenya to improve access to maternal, newborn, and child health medicines across Africa through the B2B marketplace procurement platform.

6CHAN Nigeria (Christian Health Association of Nigeria)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Axmed partners with CHAN Nigeria to improve access to maternal, newborn, and child health medicines across Africa through the B2B marketplace procurement platform.

axmed.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Ghana-based health tech company operating a pharmaceutical supply chain and inventory-financing platform across Africa. Directly comparable to Axmed in serving African healthcare buyers with consolidated pharmaceutical procurement and financing.

TypeDirect peer
Description

Kenya-based pharmaceutical inventory-management and distribution-as-a-service platform serving African pharmacies and clinics. Highly comparable B2B pharma distribution model with embedded financing, mirroring Axmed's RIFF-driven approach.

TypeDirect peer
Description

Nigeria-based B2B pharmaceutical e-commerce and distribution platform connecting pharmacies and hospitals with verified manufacturers. Direct marketplace competitor to Axmed in West Africa.

TypeDirect peer
Description

Nigeria/US-based digital pharmaceutical marketplace and quality-verification platform serving African buyers. Comparable two-sided B2B pharma marketplace targeting LMIC procurement.

TypeDirect peer
Description

Kenya-based inventory-financing and pharmaceutical distribution platform for African pharmacies. Closely mirrors Axmed's combination of B2B procurement with embedded working capital.

TypeDirect peer
Description

Nigeria-based anti-counterfeit and supply chain authentication platform for pharmaceuticals in emerging markets. Comparable in addressing trust and quality-assurance gaps in African pharmaceutical supply chains.

TypeDirect peer
Description

India/US-based pharmaceutical supply chain verification and patient-engagement platform serving emerging markets. Adjacent but comparable in enabling pharmaceutical supply integrity in LMICs.

TypeEmerging player
Description

US/Rwanda-based autonomous medical delivery service operating in several African countries. Comparable in building healthcare logistics infrastructure for LMICs, though focused on last-mile delivery rather than B2B procurement.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Axmed

Healthcare Procurement Marketplaceaxmedrx.com

Axmed is a Basel-headquartered B2B digital marketplace that aggregates demand from governments, NGOs, and healthcare procurers in low- and middle-income countries to procure essential medicines directly from vetted global pharmaceutical suppliers at lower cost.

What Axmed does

Axmed is a Basel, Switzerland-headquartered B2B digital marketplace that connects healthcare procurers in low- and middle-income countries (LMICs) with vetted global and regional pharmaceutical suppliers. Founded in 2024 with a regional hub in Nairobi, Kenya, the company targets governments, NGOs, and mission-driven private procurers in Sub-Saharan Africa and other emerging markets, addressing fragmented LMIC demand where traditional procurement markups of around 250% are commonplace. Its integrated platform combines a marketplace that aggregates demand and enables direct manufacturer contracting, a Logistics SaaS layer that coordinates with top global logistics partners, a Global Health Advisory service for procurement strategy, and embedded financing through the Revolving Inventory Financing Facility (RIFF) and a $5 million Gates Foundation-backed Matching Fund for maternal, newborn, and child health (MNCH) procurement. Axmed caps marketplace markup at 10% and reports redeploying 30% of profits back into the health systems it serves, while claiming average cost savings of around 35% for customers.

The business operates a transaction-fee model capped at 10%, supplemented by managed-services revenue from logistics coordination and financing arrangements, with go-to-market executed through enterprise field sales to governments and institutional buyers alongside partnership-driven introductions via NGOs and donor ecosystems. Named customers and partners include the Government of Burkina Faso ($7M REACH programme agreement for up to 16 million doses of azithromycin), LifeNet International, Every Pregnancy, MEDS Kenya, CHAN Nigeria, and Emcure Pharmaceuticals. By year-end 2025, Axmed reported reaching 4.2 million patients (up from ~750,000 in 2024), delivering over 1,800 metric tonnes of healthcare products across 5,000+ SKUs in 10+ therapeutic areas, with 130+ commercially active procurers and suppliers and 12x year-on-year revenue growth.

The company has raised approximately $13 million in total capital, comprising a $2 million seed round led by Founderful Ventures and roughly $11 million in non-dilutive grants from the Bill & Melinda Gates Foundation, and has publicly targeted operating in 20+ countries by end of 2026 and reaching 50 million patients within three years and 100 million within five years. Management includes co-founders Emmanuel Akpakwu (CEO), Felix Ohnmacht (CCO), Sofía Radley Searle (COO), and Mattia Albergante (CTO).

Axmed firmographics

Firmographics
Name
Axmed
Legal name
Axmed
Website
https://axmedrx.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
51–100 employees
Short description
Axmed is a Basel-headquartered B2B digital marketplace that aggregates demand from governments, NGOs, and healthcare procurers in low- and middle-income countries to procure essential medicines directly from vetted global pharmaceutical suppliers at lower cost.
Ownership category
akta.pro rank

Axmed industry classification

Industry
Product category
Healthcare Procurement Marketplace
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Wholesale Trade Agents and Brokers (42512)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYBPAMAGAD
B2B Marketplaces & Wholesale Platforms
Business & Public Services/Web, Mobile & Digital Platforms/E-commerce Marketplaces & Shopping Platforms
SECONDARYHLAIAKAA
Pricing & Contracting Strategy
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYHLAIAKAI
Channel & Trade Strategy (Gross-to-Net, Distribution Economics)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing

Keywords

  • B2B healthcare marketplace
  • Medical procurement platform
  • Pharmaceutical supply chain
  • Global health logistics
  • Medicine financing solutions

Where Axmed is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Axmed business model

Business model
GTM type
B2B
Offering type
Digital Commerce or Content
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Marketplace Transaction Fees: Axmed operates a B2B marketplace that connects healthcare procurers with suppliers. The company caps its markup at 10% and redeploys 30% of its profits back into health systems it serves, indicating a transaction-based revenue model with a social-impact pricing structure.
  2. Logistics and Financing Services: Integrated financing solutions and logistics support are embedded in the platform, with the Revolving Inventory Financing Facility (RIFF) providing capital access to procurers. Revenue is derived from financing arrangements and logistics coordination services.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goPlatform access and marketplace

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Axmed product offering

Product offering

Core offering

Axmed operates a B2B digital marketplace that aggregates fragmented demand from healthcare procurers across low- and middle-income countries and connects them directly with vetted pharmaceutical manufacturers and suppliers. The platform integrates demand aggregation, price transparency, logistics coordination, and trade financing (RIFF and a $5M Matching Fund) to reduce medicine procurement costs by over 35% for governments, NGOs, and mission-driven private procurers in LMICs.

Product overview

Axmed operates a unified B2B technology platform for medicine procurement in low- and middle-income countries, comprising three core products: the Axmed Marketplace (B2B marketplace connecting procurers with suppliers), Logistics SaaS (end-to-end logistics support), and Global Health Advisory (GHA) services. The platform is complemented by two integrated financing solutions: the Revolving Inventory Financing Facility (RIFF) for affordable capital access and the $5M Axmed Matching Fund for MNCH procurement, all designed to work together to reduce costs by over 35% while expanding access to essential medicines across Africa and emerging markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Axmed Marketplace A global B2B marketplace connecting healthcare procurers in low- and middle-income countries with vetted pharmaceutical suppliers. The platform aggregates fragmented demand to negotiate directly with manufacturers, reducing procurement costs by over 35% and providing access to 5,000+ products across 10+ therapeutic areas.
  • Logistics SaaS Integrated end-to-end logistics solution connecting buyers with top global logistics partners to streamline delivery of medicines and healthcare products across LMICs.
  • Global Health Advisory (GHA) Advisory service supporting governments and institutional procurers with procurement strategy, health system strengthening, and access to capital for essential medicines procurement.
  • Revolving Inventory Financing Facility (RIFF) An integrated supply capital facility and trade financing solution that bridges access to finance with access to quality medicines, empowering third-sector procurers to stock life-saving products in emerging markets.

Quantifiable outcome

  • 4.2 million patients reached in 2025, up from 750,000 in 2024
  • +5 more outcomes

Companies that use Axmed

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Axmed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Axmed partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • Government of Burkina Faso (REACH Programme)coreStrategic or Co-development Partner · 19 March 2026$7 million long-term supply agreement under the Resiliency through Azithromycin for Children (REACH) programme to deliver up to 16 million doses of quality-assured azithromycin to children under five in Burkina Faso over three years, supporting reduction of preventable child mortality from bacterial infections. The agreement operates through Burkina Faso's national health ecosystem.
  • LifeNet InternationalcoreStrategic or Co-development Partner · 18 December 2025Transformative partnership to expand access to essential maternal and newborn health products in Africa. LifeNet provides healthcare capacity building and training, while Axmed provides its procurement platform for medical supplies. The collaboration has already contributed to zero maternal deaths at a clinic in Northern Ghana and spans across underserved regions.
  • Every PregnancycoreStrategic or Co-development PartnerPartnership to enhance access to affordable essential medicines for mothers and babies affected by conflict and crisis. Every Pregnancy partners gain access to affordable and quality medicines through Axmed's B2B marketplace, rooted in a shared mission to ensure safe pregnancies and healthy babies.
  • Emcure PharmaceuticalscoreStrategic or Co-development PartnerUnite to combat maternal and newborn mortality and promote equitable healthcare access. The collaboration combines Emcure's pharmaceutical portfolio with Axmed's procurement platform to transform global health outcomes.
  • MEDS Kenya (Mission for Essential Drugs and Supplies)coreStrategic or Co-development PartnerAxmed partners with MEDS Kenya to improve access to maternal, newborn, and child health medicines across Africa through the B2B marketplace procurement platform.
  • CHAN Nigeria (Christian Health Association of Nigeria)coreStrategic or Co-development PartnerAxmed partners with CHAN Nigeria to improve access to maternal, newborn, and child health medicines across Africa through the B2B marketplace procurement platform.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Axmed competitors and assessment

Company assessment

Direct peers

  • mPharma: Ghana-based health tech company operating a pharmaceutical supply chain and inventory-financing platform across Africa. Directly comparable to Axmed in serving African healthcare buyers with consolidated pharmaceutical procurement and financing.
  • Field Intelligence: Kenya-based pharmaceutical inventory-management and distribution-as-a-service platform serving African pharmacies and clinics. Highly comparable B2B pharma distribution model with embedded financing, mirroring Axmed's RIFF-driven approach.
  • DrugStoc: Nigeria-based B2B pharmaceutical e-commerce and distribution platform connecting pharmacies and hospitals with verified manufacturers. Direct marketplace competitor to Axmed in West Africa.
  • RxAll: Nigeria/US-based digital pharmaceutical marketplace and quality-verification platform serving African buyers. Comparable two-sided B2B pharma marketplace targeting LMIC procurement.
  • Shelf Life: Kenya-based inventory-financing and pharmaceutical distribution platform for African pharmacies. Closely mirrors Axmed's combination of B2B procurement with embedded working capital.
  • Sproxil: Nigeria-based anti-counterfeit and supply chain authentication platform for pharmaceuticals in emerging markets. Comparable in addressing trust and quality-assurance gaps in African pharmaceutical supply chains.
  • PharmaSecure: India/US-based pharmaceutical supply chain verification and patient-engagement platform serving emerging markets. Adjacent but comparable in enabling pharmaceutical supply integrity in LMICs.

Emerging players

  • Zipline: US/Rwanda-based autonomous medical delivery service operating in several African countries. Comparable in building healthcare logistics infrastructure for LMICs, though focused on last-mile delivery rather than B2B procurement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Axmed social profiles

Digital presence

Axmed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Axmed leadership team

Management profile

Number of profiles

Profiles4 records

Axmed funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Axmed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axmed

What does Axmed do?

Axmed operates a B2B digital marketplace that aggregates fragmented demand from healthcare procurers across low- and middle-income countries and connects them directly with vetted pharmaceutical manufacturers and suppliers. The platform integrates demand aggregation, price transparency, logistics coordination, and trade financing (RIFF and a $5M Matching Fund) to reduce medicine procurement costs by over 35% for governments, NGOs, and mission-driven private procurers in LMICs.

Is Axmed a public or private company?

Axmed is a private company. It is classified as venture growth investor backed and is currently operating.

When was Axmed founded?

Axmed was founded in 2024. It employs 51 to 100 people.

Where is Axmed based?

Axmed is headquartered in Basel, Switzerland, in the Europe region.

How does Axmed make money?

Two revenue lines are on record. Marketplace Transaction Fees are the primary driver. The others are logistics and Financing Services.

Who are Axmed's main competitors?

Direct peers on record are mPharma, Field Intelligence, DrugStoc, RxAll, Shelf Life, Sproxil and PharmaSecure. Zipline is listed as an emerging player.

Does Axmed have an API?

No public API is recorded for Axmed.

What industry is Axmed in?

Axmed's product category is Healthcare Procurement Marketplace. Its primary akta.pro industry code is BPAMAGAD, B2B Marketplaces & Wholesale Platforms, with a secondary code of HLAIAKAA, Pricing & Contracting Strategy. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageBio Usawa and Axmed Partner to Expand Access to Affordable Biologic Medicines Across AfricaBio Usawa and Axmed announced a strategic collaboration to expand access to affordable biologic medicines across African health systems. The partnership will focus on ophthalmology and retinal diseases, starting with BioUcenta, a ranibizumab biosimilar, and will use Axmed's digital procurement platform to improve demand visibility and procurement efficiency.startupticker.chNine Swiss startups recognized globallySwiss startups received recognition across three international rankings, including two in Fast Company's Most Innovative Companies list. Four placed in the FoodTech 500 top 100, and Flyability won Best Sustainability Scale Up. Lemna Bio and Beech Biotech also secured grants and program support.PR NewswireAxmed Signs $7M Supply Agreement Under the Resiliency through Azithromycin for Children (REACH) Programme to Supply Up to 16 Million Doses of Quality-Assured Medicines in Burkina FasoAxmed announced a $7 million long-term supply agreement to deliver up to 16 million doses of quality-assured essential medicines to children under five in Burkina Faso over three years, supporting the country's participation in the Resiliency through Azithromycin for Children (REACH) programme. The partnership leverages Axmed's digital procurement platform to aggregate demand, increase market transparency, and provide competitive pricing while preserving government sovereignty over procurement decisions. The initiative aims to reduce preventable child deaths from common bacterial infections such as pneumonia, sepsis, and diarrhoea in high-mortality settings across sub-Saharan Africa.MorningstarAxmed Signs $7M Supply Agreement Under the Resiliency through Azithromycin for Children (REACH) Programme to Supply Up to 16 Million Doses of Quality-Assured Medicines in Burkina FasoAxmed announced a $7 million long-term supply agreement to deliver up to 16 million doses of quality-assured essential medicines to children under five in Burkina Faso over three years, supporting the Resiliency through Azithromycin for Children (REACH) programme aimed at reducing preventable child mortality from bacterial infections. The partnership leverages Axmed's digital procurement platform to aggregate demand, connect with vetted manufacturers, and deliver cost savings compared to market benchmarks while maintaining quality standards approved by Stringent Regulatory Authorities. The agreement operates through Burkina Faso's national health ecosystem, enabling the government to access global markets with greater transparency and sovereignty over procurement decisions.Health Policy WatchUnlocking The Power Of The Private Sector For Stronger Health SystemsAxmed, a Swiss-based for-profit social enterprise spinoff of the Gates Foundation, has launched a B2B technology platform for medicine procurement in low- and middle-income countries, reaching 4.2 million patients with a 35% average savings on medicines and health products. The 2025 collapse of USAID served as a turning point that fast-tracked Axmed's deployment, which is now expanding to more than 20 LMIC countries, primarily in Africa, supported by a second $5 million Gates Foundation grant. At the Geneva AIDEX 2025 conference, experts highlighted how private sector engagement through digital platforms, pooled procurement, and new financing mechanisms can address chronic healthcare system challenges including market fragmentation, regulatory complexity, and supply chain inefficiencies.startupticker.chFemale Founder News #23February's female founder ecosystem saw over twenty startups advance through grants and innovation loans, alongside two healthtech acquisitions signalling continued sector consolidation. Hamilton Medical acquired Bern-based STIMIT AG to integrate its competencies into the Hamilton Group, while Swiss Rockets acquired U.S. life sciences company Complete Genomics to support targeted cancer therapies and next-generation vaccine development. Global health and logistics company Axmed received a $6 million grant from the Gates Foundation to scale its essential medicines sourcing and distribution platform across Africa.StartupmafiaBasel’s Axmed secures €5M Gates Foundation grant to scale affordable medicines access across low-income countriesAxmed, a Swiss HealthTech company headquartered in Basel, has been awarded a €5 million non-dilutive grant from the Bill & Melinda Gates Foundation—the Foundation's second major grant to the company following a prior €4.2 million commitment—to accelerate expansion of its B2B procurement platform across Africa. The company, which has now raised €11 million in total capital since its 2023 founding, delivered over 1,800 metric tonnes of healthcare products to 4.2 million patients in 2025, achieving 12x year-on-year revenue growth and generating 30–35% cost savings for customers through demand aggregation and price transparency. Axmed is targeting operations in more than 20 countries by end of 2026 and has set a goal of reaching 50 million patients within three years, positioning itself as a core infrastructure layer for essential medicines procurement in underserved markets.StartbaseAxmed receives 6 million US dollars in funding for healthcare logisticsAxmed, a HealthTech platform focused on healthcare logistics, has received a $6 million non-dilutive grant from the Gates Foundation to expand its B2B procurement and logistics platform for low- and middle-income countries, bringing total raised capital to $13 million. The platform, which bundles demand and coordinates international supply chains to reduce costs by 30-35%, delivered over 1,800 tons of medical goods and reached 4.2 million patients in 2025, up from 750,000 the prior year. The company recorded a twelve-fold year-on-year increase in sales and aims to be active in over 20 countries by 2026, targeting 50 million people within three years.AxmedAxmed Secures $6M Grant Funding to Scale the Global Infra...Axmed, a health technology company headquartered in Switzerland with regional operations in Kenya, has been awarded $6 million in non-dilutive grant funding from the Gates Foundation to expand its B2B procurement and logistics platform for essential medicines across low- and middle-income countries. The funding, building on a prior $5 million grant and bringing total capital raised to $13 million, will accelerate Axmed's Africa expansion after the company reported 12x year-on-year revenue growth and reached 4.2 million patients in 2025, up from approximately 750,000 in 2024. The company aims to operate in more than 20 countries by the end of 2026 and reach 50 million patients within three years.Pulse 2.0Axmed: $6 Million Grant Secured To Expand Global Access To MedicinesAxmed secured $6 million in non-dilutive grant funding from the Gates Foundation to expand access to medicines in low- and middle-income countries. The platform delivered over 1,800 metric tonnes of products and reached 4.2 million patients in 2025, up from 750,000 in 2024. The company plans to operate in over 20 countries by 2026 and target 50 million patients within three years.